Post by
Mbxwatcher on May 16, 2023 2:44pm
Great Announcement
It is a good deal, and welcome news......Over the long haul I think this deal supports a large value opportunity and a solid addition to the productive portfolio. I think the terms of the deal are favourable, as the partner spends all the money.....I do think that the FDA meeting milestone, will temper the markets enthusiasm until they pass that hurdle......not saying the hurdle is an issue, but the FDA is the great unkown for so many of these drugs, that I anyone investing in this space, gets cautious when they need go be involved. I could be wrong but i think passing that milestone will cause another lift.
I also think that the lack of enthusiasm was predictable and inevitable. Failed VTM, stalled QAPS and dining out on lower margin antigens are not what the market wants to hear. Nothing I heard today made me feel better about the inevitability of new QAPS deals.
Dont want to rain on the parade...I am truly happy about the kInlytic deal, but the market reaction is about what I think it would be....real revenue from this deal is a long way off, and the current staples are underperforming.......
Comment by
wizzdumb on May 16, 2023 3:28pm
Considering Kinlytic was a totally free option I figured it was worth more than few pennies, although your comment on FDA milestone is a good one. I think the market/analyst negativity due to past failed promises was greater than I personally anticipated. Cameron and team will just need to keep executing and the sentiment will eventually change.